To explore the effects of androgen-deprivation therapy (ADT) on general, disease-specific and hormone-specific health-related quality of life (HRQOL) among minority men. METHODS: Men enrolled in a state-funded program, providing free prostate cancer treatment for underserved men, were recruited, if they had received at least 3 months of continuous ADT and/or other forms of primary treatment. HRQOL was assessed with validated measures including the RAND Medical Outcomes Study 12-item Health Short Form Survey (SF-12), the UCLA Prostate Cancer Index Survey and the Expanded Prostate Cancer Index Composite Survey. Repeated measures analysis was performed to evaluate the association between clinical and sociodemographic covariates with HRQOL. RESULTS: We enrolled 322 men, including 94 on ADT and 228 who received other forms of treatment. When controlling for patient characteristics, men receiving ADT had poorer outcomes relative to sexual function (Po0.01), sexual bother (Po0.01), hormonal function (Po0.01) and hormonal bother (P ¼ 0.02). ADT use was significantly associated with worsening sexual function (Po0.01) and sexual bother (P ¼ 0.01) over two years compared with non-ADT users. Analysis also demonstrated significant differences between whites, Hispanics and Others (African American (n ¼ 43, 16%), Asian (n ¼ 13, 5%), multiracial (n ¼ 1, 0.4%), Native American (n ¼ 1, 0.4%) and other (n ¼ 9, 3%)) relative to urinary bother (P ¼ 0.01), urinary function (P ¼ 0.01) and hormonal bother (P ¼ 0.03). ADT users had better urinary function and less bother than non-ADT users among the Other group, while the opposite was true for whites and Hispanics. For hormonal bother, ADT use was associated with worse outcomes across all three race/ethnicity groups; however, Hispanics were less bothered by their hormonal symptoms than whites or Others. CONCLUSION: Men of disadvantaged backgrounds on hormone therapy for prostate cancer experience declines in sexual and hormonal HRQOL. Whites and non-whites on ADT have significantly different HRQOL outcomes.
INTRODUCTION
In a transitioning healthcare system in difficult economic times, it is important to determine how treatment-related risks affect vulnerable populations. Hispanics, one of the fastest growing US ethnicities, account for 16% of the population. African Americans, the largest US racial minority group, comprise 13% of the population. 1 As Hispanics, African Americans and other minorities account for such a significant proportion of the US population, it is inevitable that these groups will suffer from conditions and treatment-related side effects that affect their quality of life. Prostate cancer, one such disease, is the most commonly diagnosed noncutaneous cancer among US men, including Latinos and African Americans. 2 Men of color are more likely diagnosed at a later stage disease and as a result are more likely treated with androgen-deprivation therapy (ADT). 3 ADT lowers testosterone levels and has been shown to improve survival in men with prostate cancer. 4 --8 Over the past decade, ADT use has risen sharply with a dramatic increase in the use of ADT in conjunction with radiation therapy and with earlier stage disease. 4 ADT continues to be the primary means of treatment for recurrent and metastatic prostate cancer 4, 5 despite its multiple adverse effects. 6 --9 ADT puts men at risk for adverse psychological effects and diminished health-related quality of life (HRQOL), sometimes referred to as ADT syndrome. This consists of depression, anxiety, fatigue and memory difficulties. 8 Additionally, the decreased libido and erectile dysfunction associated with ADT threaten masculine identity. 6, 9, 10 HRQOL related to ADT has been explored in many studies indicating that ADT is generally associated with diminished HRQOL. 6, 7, 10 On the basis of these prior studies, we hypothesized that men receiving hormone therapy would have lower HRQOL compared with men receiving other forms of treatment. Furthermore, among ADT users, we posited that minority men in our study, including Hispanics, African Americans, Asians and other racial --ethnic minorities, would have worse HRQOL than non-Hispanic whites.
We hypothesized that minority men on ADT in our study population would have lower HRQOL compared with nonHispanic whites because prior research has demonstrated that minority men, including Hispanics and African-Americans, suffer disproportionally from urologic cancer screening and treatments compared with whites. 11, 12 In addition, the low socioeconomic status of our study population differs from that of other studies and may be an influential cause for decrease in HRQOL. Prior studies have shown that low-income patients have lower selfesteem and self-efficacy with regards to prostate cancer treatment. 13, 14 This evidence indicates that our study population may potentially have socioeconomic barriers in addition to treatment side effects that may cause a decrease in quality of life.
MATERIALS AND METHODS Subjects
We included 322 men with prostate cancer enrolled in IMPACT (Improving Access, Counseling and Treatment for Californians with Prostate Cancer), a state-funded program that provides free prostate cancer treatment for men who are uninsured or underinsured and low-income (www. california-impact.org). Men with household incomes under 200% of the Federal Poverty Level are eligible for the program. Financially eligible men with biopsy-proven prostate cancer are assigned to a primary urologist, case coordinator and nurse case manager. The majority of men enrolled in IMPACT are of color, younger, with advanced stages of prostate cancer. 6, 15 In August 2010, there were 965 men enrolled in IMPACT who had extractable treatment data. Of these men, 643 were enrolled in the University of California, Los Angeles Men's Health Study, a longitudinal survey of clinical and patient-centered outcomes. After excluding men who received intermittent ADT therapy or hormone therapy other than Lupron, a total of 447 men remained. Of these men, 322 men had baseline and follow-up survey data. The 322 men received ADT for 3 months or longer and/or other forms of primary treatment including radical prostatectomy (RP), radiation therapy (RT), RT þ RP, or no treatment at all. The study population comprised of various racial-ethnic groups including whites, Hispanics, African Americans and Others. The Other group consisted of men of Asian, Native American and multi-racial backgrounds. Race/ ethnicity was self-reported.
Data collection
All men enrolled in IMPACT are asked to participate in the University of California, Los Angeles Men's Health Study (MHS). Data on general, diseasespecific and hormone-specific HRQOL are collected through telephone interviews and self-administered questionnaires at enrollment and every six months thereafter. For this study, we analyzed up to 48 months of data. Data pertaining to ADT start dates and length of treatment, race/ethnicity, number of comorbidities and other demographic and clinical information were also obtained from the Men's Health Study database and through medical record abstraction. All procedures were approved by the University of California, Los Angeles Office for Protection of Research Subjects and were compliant with the Health Insurance Portability and Accountability Act. Long-term quality of life and androgen-deprivation therapy C Sevilla et al
Instruments
We measured general HRQOL with the RAND Medical Outcomes Study 12-item Health Short Form Survey (SF-12), version 2, a 12-item survey that quantifies HRQOL into eight domains and two summary scores, the physical and mental component summaries. This 12-item questionnaire is an adaptation of the SF-36 and correlates highly with the SF-36 (r 2 ¼ 0.938 and 0.905, respectively). The SF-12 is scored from 0 to 100, with higher scores indicating better outcomes. It has high test --retest reliability (r 2 ¼ 0.89 and 0.76, respectively) and empirical reliability with diverse populations. 16 We evaluated disease-specific HRQOL with the University of California, Los Angeles Prostate Cancer Index (PCI) short form, a 15-item questionnaire that assesses urinary, bowel, and sexual function and bother. The function scales measure incontinence, proctitis, and erectile difficulties, and the bother scales assess how troubled the patient is by such symptoms. PCI scales are scored from 0 to 100, with higher scores indicative of better HRQOL. The PCI is reliable and valid in men with and without prostate cancer. 16 --19 We measured hormone-specific HRQOL with the two hormone domains of the Expanded Prostate Cancer Index Composite (EPIC), an expansion of the PCI. The EPIC has 50 items addressing function and bother. Scores are summed in each of 4 domains (urinary, bowel, sexual and hormonal). For this study, only the hormonal domains were utilized with questions pertaining to the following symptoms: hot flashes, breast tenderness, depression and fatigue. Domains are scored from 0 to 100, with higher scores indicating better outcomes. It has robust internal consistency (Cronbach's alpha X0.82) and test --retest reliability (r 2 X0.80).
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Statistical analysis
We categorized men based on treatment with ADT for at least 3 months. For non-ADT users, time one was at time of enrollment in the Men's Health Study. For ADT users, time one was the time point at which their first MHS survey was completed after being sustained on ADT for at least 3 months, which may have been at time of enrollment or several months after enrolling in the MHS. Considering that the ADT group had various lengths of treatment before MHS enrollment, we calculated the months on ADT at time one survey and included it as a covariate in our multivariate analysis. We used chisquare analysis to explore univariate associations between ADT treatment and categorical variables including primary treatment, age, education, ethnicity, number of comorbid conditions, and body mass index. We also performed independent t-tests on the continuous variables including age and monthly household income. ADT-stratified time one mean scores were calculated for general (SF-12), disease-specific (PCI) and hormone-specific (EPIC) quality-of-life outcomes and were compared with t-tests. For our multivariate analyses we used generalized linear mixed modeling for repeated measures. We evaluated the physical and mental component summaries, urinary, bowel, sexual , and hormonal function and bother as outcomes. Our base model for all outcomes included three terms: ADT treatment, time and their interaction to explore differences in outcome trajectories by ADT use. Irrespective of significance in univariate analysis, several covariates were incorporated a priori if previously known to influence the quality of life in men with prostate cancer. Covariates included primary treatment, months on ADT, age, education and race. Body mass index and number of comorbidities were incorporated in the final model, if significant. We also explored nonlinear trends by ADT status by including a term for time 2 by ADT. Lastly, to evaluate the potential moderation of race/ethnicity on the effect of ADT on QOL outcomes, we added an interaction of race by ADT to the final model. For all outcomes, we tested for random intercept and random time. Covariance was unstructured for all models. Two-tailed significance was set at Pp0.05. All statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA). Table 1 demonstrates the clinical and demographic characteristics of the study sample. Nearly one-third of the study population received ADT treatment for 3 months or longer. Of the men who received ADT, the mean amount of time on ADT was 7.5 months. Mean age at baseline was 60 years and the vast majority of men (89%) were of an ethnic minority group (63% Hispanic, 16% African American and 10% other). About half of the men had not completed high school; average monthly household income was US$824. Almost one-half reported one or more comorbidities (43%) and almost three-fourths had a body mass index that was categorized as overweight or obese. ADT users were significantly older than non-ADT users (61 vs 59, P ¼ 0.01). For primary treatment, ADT users had a higher percentage of radical prostatectomy (50% vs 20%), followed by no definitive treatment (35% vs 4%) compared with non-ADT users (Po0.01). Non-ADT users had a higher percentage of radiation therapy compared with ADT users (60% vs 5%, Po0.01). There were no other statistically significant differences in demographic or clinical characteristics stratified by ADT treatment. Table 2 presents time one mean scores for HRQOL measures including the SF-12, PCI and EPIC. ADT users had higher mean scores compared with non-ADT users on urinary function (76 vs 64, Po0.01). ADT users had lower mean scores compared with non-ADT users for general health (43.1 vs 49.7, P ¼ 0.04), hormonal function (67 vs 78, Po0.01) and hormonal bother (76 vs 82, P ¼ 0.03). We noted no other statistically significant differences for general, prostate-specific, or hormone-specific HRQOL measures. We noted a trend in sexual function and emotional well being, where ADT users had worse mean scores than non-ADT users (P ¼ 0.09 and P ¼ 0.11, respectively). Long-term quality of life and androgen-deprivation therapy C Sevilla et al Table 3 and Figure 1 present multivariate mixed models for all HRQOL outcomes. After controlling for months on ADT and other covariates, ADT treatment had a significant association with poorer outcomes in sexual function (Po0.01), sexual bother (Po0.01), hormonal function (Po0.01) and hormonal bother (P ¼ 0.02). When exploring the trend over time, ADT users had worsening sexual function (Po0.01) and sexual bother (P ¼ 0.01) over time, whereas non-ADT users remained constant. When investigating the time 2 by ADT interaction, physical composite summary (P ¼ 0.05), bowel bother (P ¼ 0.02), hormonal function (Po0.01) and hormonal bother (Po0.01) were found to be significant. For these outcomes, ADT users had worsening scores over time compared with non-ADT users who had improvement in scores over time. Both groups eventually experienced constant or slightly improved scores after 18 months.
RESULTS
We evaluated the interaction effect of race/ethnicity and ADT on quality of life controlling for time and other covariates ( Figure 2 ). The category of race/ethnicity incorporated three different groups including non-Hispanic whites, Hispanics and Others (African American (n ¼ 43, 16%), Asian (n ¼ 13, 5%), multiracial (n ¼ 1, 0.4%), Native American (n ¼ 1, 0.4%) and other (n ¼ 9, 3%)). Using whites as the reference group, the interaction between race/ethnicity and ADT was significant for urinary function (Po0.01), urinary bother (P ¼ 0.01) and hormonal bother (P ¼ 0.03). ADT users had better urinary function and less bother than non-ADT users among the Other race group, while ADT users had worse urinary function and more bother than non-ADT users among whites and Hispanics. For hormonal bother, ADT use was associated with worse outcomes across all three race/ethnicity groups; however, Hispanics were less bothered by their hormonal symptoms than whites or Others.
DISCUSSION
We found that men enrolled in IMPACT who received ADT experience worse disease-specific and hormone-specific HRQOL than men receiving other forms of treatment. Of particular importance was that not only were sexual and hormonal outcomes poorer in men receiving ADT, but also that they continued to decline past one year, while those not on ADT had Long-term quality of life and androgen-deprivation therapy C Sevilla et al improved or stable scores. Few studies have examined the impact of ADT on racial disparities in men with prostate cancer. This is the first study to examine the effects of ADT on HRQOL in a disadvantaged population of men with prostate cancer. We sought to determine whether HRQOL was diminished in men on ADT enrolled in the IMPACT program who are already burdened by low income and inadequate insurance. To further understand how ADT influences men of minority races/ethnicities, we also compared the effects of ADT on quality of life in whites, Hispanics, African Americans and other racial-ethnic groups. We found significant differences between whites and non-whites (Hispanics and Others) receiving hormone therapy. Our comparison of mean scores on quality of life measures stratified by ADT treatment yielded several findings. That men on ADT had lower HRQOL mean scores in general health compared with non-ADT users, is a finding supported by Dacal et al. whose study found that men on ADT reported significantly poorer quality of life in the area of general health compared with men not receiving ADT (Po0.001). 21 This finding was independent of the length of ADT treatment. As expected, our study also found that in this specific population, men on ADT suffered from lower hormonal function and were more bothered by their symptoms compared with non-ADT users after being on ADT for at least 3 months.
With regard to primary treatment, non-ADT users received a significantly higher percentage of RP and/or RT compared with ADT users. Furthermore, men not receiving ADT had poorer urinary function compared with men on ADT. Because RPRT directly affect the urinary system, 22, 23 it is expected that those who received these procedures more frequently (non-ADT users) would have poorer urinary function than those who received ADT alone. Second, underserved men with prostate cancer are often diagnosed at a later stage and receive ADT as primary treatment. It is possible that the ADT users in our study did not always receive other forms of primary treatment because they presented with later stage disease.
When controlling for all covariates, including months on ADT, we determined that disease-specific and hormone-specific quality of life outcomes, including sexual function, sexual bother, hormonal function and hormonal bother were poorer in ADT users compared with non-ADT users. These scores were expected to be lower in men receiving ADT due to the lowering of testosterone, which can cause symptoms such as hot flashes, decreased sexual function, depression and fatigue. 24 Furthermore, this finding highlights that regardless of time on hormone therapy, men who have been on ADT for at least 3 months will experience a decrease in disease-specific and hormone-specific quality of life compared with men receiving other treatments.
The worsening sexual function and sexual bother in ADT users over time corroborated prior studies looking at the effects of ADT on masculine identity in which men were noted to have a decline in sexual function after treatment with ADT. 25, 26 Basaria et al. determined that men receiving ADT for at least 12 months had lower sexual function (decrease in desire, arousal and frequency of spontaneous early morning erections (P ¼ 0.0001) compared with normal healthy men and men with prostate cancer receiving other forms of treatment. 26 Potosky et al. found that, among men with good erectile function before prostate cancer diagnosis, 80% men receiving ADT reported erectile dysfunction after one year compared with 30% of those receiving no treatment (Po0.001). 25 However, these studies did not look at the effects of ADT past one year. Our findings demonstrate that men continue to see a decline in sexual function and increase in bother up to two years while on ADT compared with men not receiving ADT. This has clinical significance in determining long-term ADT use for patients concerned with sexual side effects.
Our study found that the nonlinear time 2 trend by ADT was significantly associated with general, disease-specific and hormone-specific HRQOL outcomes. It was determined that men receiving ADT have poorer outcomes in the areas of physical function, bowel bother, hormonal function and hormonal bother. These outcomes worsened over time in men receiving ADT and improved over time in men not receiving hormone therapy. Prior data is inconsistent with our findings regarding general HRQOL outcomes. Although some studies suggest that physical function improves after hormone therapy, 19 other studies show no difference or worsening physical function. 27, 28 However, prior literature is consistent with our findings regarding hormonespecific HRQOL, in which men on ADT suffer from declining hormonal function and are more bothered by their hormonal symptoms (hot flashes, breast tenderness, fatigue and depression) compared with men receiving other forms of treatment.
--31
Although not reported as frequently, a previous study also noted a decrease in bowel function and worsening bowel bother associated with ADT. 32 As a result of lower education, it may be possible that disadvantaged men in our study population had unrealistic expectations of their treatment and, therefore, were more bothered by symptoms that prior literature has not commonly shown to be associated with hormone therapy.
When exploring the interaction of race/ethnicity by ADT on HRQOL, we found significant differences between whites and nonwhites for urinary function, urinary bother and hormonal bother. It was noted that in men receiving ADT, Hispanics were less bothered by their hormonal symptoms than Others or whites. Reasons for this may be due to cultural beliefs and stigma associated with symptoms of ADT including depression and fatigue. Prior studies have recognized that Hispanics tend to view admittance of illness, both mental and physical, as a sign of weakness. 33 It is plausible that Hispanics in our study were less likely to report being bothered by hormonal symptoms because it would be considered an indication of failure or weakness.
It is unclear why ADT use was associated with better urinary function and lower urinary bother in the Other group compared with Hispanics and whites. Considering the Other group, consisted of a small sample size, further studies are needed with larger study populations of varying ethnicities to determine whether the same conclusions hold.
Our study is strengthened by the use of validated surveys of general HRQOL, disease-specific HRQOL and hormone-specific HRQOL; however, it is important to note that data were collected by self-report and may be subject to social desirability and recall bias. In addition, our study was conducted with low-income men, the majority of who were Hispanic and African American; therefore, the results of this study may not be generalizable to all prostate cancer patients. Finally, our population was enrolled in a program designed to provide specialized care for prostate cancer. 
